-+ 0.00%
-+ 0.00%
-+ 0.00%

According to Taienkang, recently, Taienkang completed a capital increase for Guangdong Prokairong Biomedical Technology Co., Ltd., and signed a “strategic cooperation agreement” with Prokairong and its actual controller, Zeng Haoyu. After the capital increase settlement is completed, Taienkang obtained exclusive commercial promotion service rights for the world's first ocular surface cell therapy product MsCoHi lens project in the Chinese region. The two sides will jointly promote the commercialization of innovative achievements in ocular surface critical cell treatment.

Zhitongcaijing·08/17/2026 12:57:03
Listen to the news
According to Taienkang, recently, Taienkang completed a capital increase for Guangdong Prokairong Biomedical Technology Co., Ltd., and signed a “strategic cooperation agreement” with Prokairong and its actual controller, Zeng Haoyu. After the capital increase settlement is completed, Taienkang obtained exclusive commercial promotion service rights for the world's first ocular surface cell therapy product MsCoHi lens project in the Chinese region. The two sides will jointly promote the commercialization of innovative achievements in ocular surface critical cell treatment.